ARQ 197 Phase III trial MARQUEE for NSCLC is stopped - 03-Oct-2012

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. have announced that the independent Data Monitoring Committee (DMC) of the Phase III MARQUEE (Met inhibitor ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC) trial recommended the study be stopped early following a planned interim analysis, when they concluded that the study would not meet its primary endpoint of improved overall survival. Although the interim analysis showed a statistically significant improvement in progression-free survival (PFS) in the intent-to-treat (ITT) population, this benefit did not carry over to overall survival.

Related News

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

IDMC halts Phase III study of Vargatef (Boehringer) in NSCLC

FDA approves Tarceva (Genentech/Astellas) for NSCLC as detected by cobas EGFR Mutation Test

NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer

CRLX 101 (Cerulean Pharma) fails in Phase II trial for NSCLC

NICE rejects extended use of Alimta (Eli Lilly) in NSCLC

Phase III trial of Stimuvax (Merck Serono) fails to meet primary endpoint in patients with NSCLC

New Phase II trial shows combination treatment with selumetinib (AstraZeneca) has promise for patients with NSCLC

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

SAR 302503 (Sanofi) successs in JAKARTA study of Myelofibrosis

18 May 2013

Sanofi has announced that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR 302503 for Myelofibrosis versus placebo...

Read full article

Phase III study of NEPA (Helsinn and Eisai) meets endpoint in patients with Nausea

18 May 2013

Top-line results from a pivotal Phase III clinical study investigating NEPA (netupitant and palonosetron), from Helsinn and Eisai, for...

Read full article